Barclays PLC Purchases 59,582 Shares of Cryoport, Inc. (NASDAQ:CYRX)

Barclays PLC lifted its position in Cryoport, Inc. (NASDAQ:CYRX) by 272.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 81,417 shares of the company’s stock after purchasing an additional 59,582 shares during the quarter. Barclays PLC owned 0.16% of Cryoport worth $660,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the company. State Street Corp grew its holdings in shares of Cryoport by 2.8% during the 3rd quarter. State Street Corp now owns 1,003,080 shares of the company’s stock valued at $8,135,000 after purchasing an additional 27,438 shares during the last quarter. Stifel Financial Corp lifted its stake in Cryoport by 11.0% in the third quarter. Stifel Financial Corp now owns 139,745 shares of the company’s stock worth $1,133,000 after purchasing an additional 13,809 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in Cryoport during the third quarter valued at about $3,405,000. Fred Alger Management LLC grew its stake in shares of Cryoport by 49.9% during the third quarter. Fred Alger Management LLC now owns 2,698,768 shares of the company’s stock valued at $21,887,000 after buying an additional 898,481 shares during the last quarter. Finally, Thematics Asset Management increased its holdings in shares of Cryoport by 176.2% in the third quarter. Thematics Asset Management now owns 1,705,000 shares of the company’s stock worth $13,828,000 after buying an additional 1,087,800 shares during the period. 92.90% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Cryoport news, Director Ramkumar Mandalam sold 7,369 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $7.46, for a total value of $54,972.74. Following the completion of the sale, the director now directly owns 59,497 shares of the company’s stock, valued at $443,847.62. The trade was a 11.02 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jerrell Shelton sold 50,000 shares of the company’s stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $6.51, for a total transaction of $325,500.00. Following the completion of the transaction, the chief executive officer now owns 731,897 shares in the company, valued at $4,764,649.47. This represents a 6.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 109,869 shares of company stock valued at $735,673 in the last three months. Corporate insiders own 10.10% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. UBS Group lifted their target price on shares of Cryoport from $7.00 to $9.00 and gave the stock a “neutral” rating in a research note on Friday, October 18th. Roth Mkm decreased their price objective on shares of Cryoport from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, November 8th. Finally, Guggenheim began coverage on Cryoport in a research note on Thursday, December 19th. They issued a “buy” rating and a $11.00 target price on the stock. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, Cryoport currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.29.

Cryoport Stock Down 0.9 %

NASDAQ CYRX opened at $7.78 on Thursday. Cryoport, Inc. has a 12 month low of $5.32 and a 12 month high of $20.10. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48. The stock has a market cap of $384.57 million, a PE ratio of -2.30 and a beta of 1.62. The stock’s 50 day moving average is $7.49 and its 200 day moving average is $7.85.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.